31 results
8-K
EX-99.1
CLNN
Clene Inc
8 May 24
CLENE REPORTS First QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
8:01am
-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway
8-K
EX-99.3
CLNN
Clene Inc
16 Apr 24
Regulation FD Disclosure
4:06pm
that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene
8-K
EX-99.1
CLNN
Clene Inc
13 Mar 24
Clene Reports Full Year 2023 Financial Results
8:02am
-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD
8-K
EX-99.2
ysasot
29 Feb 24
Regulation FD Disclosure
8:05am
8-K
EX-99.2
0o6qu62kl1jdz93c
22 Feb 24
Regulation FD Disclosure
8:04am
8-K
EX-99.2
r3m9 ebs95i
8 Jan 24
Regulation FD Disclosure
7:07am
8-K
EX-99.3
fydwvgcxjtbt
21 Dec 23
Regulation FD Disclosure
7:00am
8-K
EX-99.2
b21j8e4mda5sd2
21 Dec 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
rld9c4a9etj1y w613bh
7 Nov 23
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
8:02am
8-K
EX-1.1
3hae06fmhyvqcj
16 Jun 23
Clene Announces Launch of Proposed Public Offering
5:06pm
424B3
4n9cd
10 Nov 21
Prospectus supplement
4:02pm
424B3
bp1 0ew8j490j7
10 Nov 21
Prospectus supplement
4:01pm
424B3
xplya 4utk8tn9m
2 Aug 21
Prospectus supplement
5:03pm